Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Cancer Res (2012) 72 (4): 969–978.

https://doi.org/10.1158/0008-5472.CAN-11-1875

Published: 14 February 2012

View articletitled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Includes: Supplementary data

Journal Articles

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su

Cancer Res (2012) 72 (3): 779–789.

https://doi.org/10.1158/0008-5472.CAN-11-2941

Published: 31 January 2012

View articletitled, Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Includes: Supplementary data

Journal Articles

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

Huisheng Wang, Sherif Daouti, Wen-hui Li, Yang Wen, Christine Rizzo, Brian Higgins, Kathryn Packman, Neal Rosen, John F. Boylan, David Heimbrook, Huifeng Niu

Cancer Res (2011) 71 (16): 5535–5545.

https://doi.org/10.1158/0008-5472.CAN-10-4351

Published: 11 August 2011

View articletitled, Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

Includes: Supplementary data

Journal Articles

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAF^V600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Brian Higgins, Kenneth Kolinksy, Zenaida Go, Hing Char, Richard Lee, Kathleen Schostack, Gideon Bollag, David Heimbrook, Fei Su, Kathryn E. Packman

Cancer Res (2011) 71 (8_Supplement): 2562.

https://doi.org/10.1158/1538-7445.AM2011-2562

Published: 15 April 2011

View articletitled, Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Journal Articles

Abstract 5036: Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

Huifeng Niu, Huisheng Wang, Sherif Daouti, Wen-Hui Li, Yang Wen, Christine Rizzo, Brian Higgins, Kathryn Packman, Neal Rosen, John F. Boylan, David Heimbrook

Cancer Res (2011) 71 (8_Supplement): 5036.

https://doi.org/10.1158/1538-7445.AM2011-5036

Published: 15 April 2011

View articletitled, Abstract 5036: Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

Journal Articles

RG7204 (PLX4032), a Selective BRAF^V600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley Kolis, Sylvia Zhao, Richard Lee, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su

Cancer Res (2010) 70 (13): 5518–5527.

https://doi.org/10.1158/0008-5472.CAN-10-0646

Published: 30 June 2010

View articletitled, RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Includes: Supplementary data

Journal Articles

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Leopoldo Luistro, Wei He, Melissa Smith, Kathryn Packman, Maria Vilenchik, Daisy Carvajal, John Roberts, James Cai, Windy Berkofsky-Fessler, Holly Hilton, Michael Linn, Alexander Flohr, Roland Jakob-Røtne, Helmut Jacobsen, Kelli Glenn, David Heimbrook, John F. Boylan

Cancer Res (2009) 69 (19): 7672–7680.

https://doi.org/10.1158/0008-5472.CAN-09-1843

Published: 01 October 2009

View articletitled, Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Includes: Supplementary data

Journal Articles

Abstract #2010: RO4929097: A potent \#947;-secretase inhibitor targeting Notch signaling

John Roberts, Christian Czech, Pascale David-Pierson, Alexander Flohr, Guido Galley, Kelli Glenn, David Heimbrook, Helmut Jacobsen, Roland Jakob-Roetne, Leopoldo Luistro, Laurence Ozmen, Kathryn Packman, Jens-Uwe Peters, Monique Schmitt, Melissa Smith, John Boylan

Cancer Res (2009) 69 (9_Supplement): 2010.

Published: 01 May 2009

View articletitled, Abstract #2010: RO4929097: A potent \#947;-secretase inhibitor targeting Notch signaling

Journal Articles

Abstract #4420: PLX4032, a selective B-Raf^V600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Fei Su, Hong Yang, Brian Higgins, Kenneth Kolinsky, Richard Lee, Kathryn Packman, Kathleen Schostack, David Heimbrook, Gideon Bollag

Cancer Res (2009) 69 (9_Supplement): 4420.

Published: 01 May 2009

View articletitled, Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Journal Articles

Abstract #4759: Preclinical profile of a potent gamma-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties

Leopoldo Luistro, Melissa Smith, Kathryn Packman, Wei He, Maria Vilenchik, Daisy Carvajal, John Roberts, James Cai, Windy Berkofsky-Fessler, Holly Hilton, Xin Wei, Michael Linn, Alexander Flohr, Roland Jacob-Roetne, Helmut Jacobsen, David Heimbrook, John Boylan

Cancer Res (2009) 69 (9_Supplement): 4759.

Published: 01 May 2009

View articletitled, Abstract #4759: Preclinical profile of a potent gamma-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties

Journal Articles

Abstract #861: Activation of the p53 pathway by MDM2 antagonists enhances antitumor effect of androgen deprivation in prostate cancer cells

Christan Tovar, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, David Heimbrook, Lyubomir Vassilev

Cancer Res (2009) 69 (9_Supplement): 861.

Published: 01 May 2009

View articletitled, Abstract #861: Activation of the p53 pathway by MDM2 antagonists enhances antitumor effect of androgen deprivation in prostate cancer cells

Journal Articles

Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

Sherif Daouti, Huisheng Wang, Wen-hui Li, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Anthony Specian, Jr., Norman Kong, Nicholas Huby, Yang Wen, Qing Xiang, Frank J. Podlaski, Yang He, Nader Fotouhi, David Heimbrook, Huifeng Niu

Cancer Res (2009) 69 (5): 1924–1932.

https://doi.org/10.1158/0008-5472.CAN-08-2627

Published: 02 March 2009

View articletitled, Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

Includes: Supplementary data

Journal Articles

A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage

Cancer Res (2008) 68 (4): 1162–1169.

https://doi.org/10.1158/0008-5472.CAN-07-2349

Published: 15 February 2008

View articletitled, A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage

Journal Articles

An optimized screen for mitotic inhibitors using cancer cells synchronized at the G2/M phase border

Osamu Kondoh, Christian Tovar, Shannon Hamilton, Ann Hoffman, David Heimbrook, Lyubomir Vassilev

Cancer Res (2007) 67 (9_Supplement): 620.

Published: 01 May 2007

View articletitled, An optimized screen for mitotic inhibitors using cancer cells synchronized at the G2/M phase border

Journal Articles

Antitumor mechanism of a novel tumor and angiogenesis inhibitor R1530

Christian Tovar, Brian Higgins, David Heimbrook, Lyubomir Vassilev

Cancer Res (2007) 67 (9_Supplement): 5429.

Published: 01 May 2007

View articletitled, Antitumor mechanism of a novel tumor and angiogenesis inhibitor R1530

Journal Articles

Small-molecule inhibitors of the p53-MDM2 interaction

Lyubomir Vassilev, Christian Tovar, Dejan Knezevic, Thelma Thompson, Zoran Filipovic, Brian Higgins, Weiguo Qing, Binh Vu, Frank Podlaski, Bradford Graves, David Heimbrook

Cancer Res (2007) 67 (9_Supplement): SY13-02.

Published: 01 May 2007

View articletitled, Small-molecule inhibitors of the p53-MDM2 interaction

Journal Articles

A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo

Laura Sepp-Lorenzino, Elaine Rands, Xianzhi Mao, Brett Connolly, Jennifer Shipman, Joanne Antanavage, Susan Hill, Lenora Davis, Stephen Beck, Keith Rickert, Kathleen Coll, Patrice Ciecko, Mark Fraley, William Hoffman, George Hartman, David Heimbrook, Jackson Gibbs, Nancy Kohl, Kenneth Thomas

Cancer Res (2004) 64 (2): 751–756.

https://doi.org/10.1158/0008-5472.CAN-03-2871

Published: 26 January 2004

View articletitled, A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAF^V600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Abstract 5036: Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

RG7204 (PLX4032), a Selective BRAF^V600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Abstract #2010: RO4929097: A potent \#947;-secretase inhibitor targeting Notch signaling

Abstract #4420: PLX4032, a selective B-Raf^V600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Abstract #4759: Preclinical profile of a potent gamma-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties

Abstract #861: Activation of the p53 pathway by MDM2 antagonists enhances antitumor effect of androgen deprivation in prostate cancer cells

Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage

An optimized screen for mitotic inhibitors using cancer cells synchronized at the G2/M phase border

Antitumor mechanism of a novel tumor and angiogenesis inhibitor R1530

Small-molecule inhibitors of the p53-MDM2 interaction

A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only